Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2022-01-19 Regulatory Filings
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming details of securities dematerialized/rematerialized for the quarter ended December 31, 2021. It is a compliance certificate issued by the company secretary and the registrar and share transfer agent. The document does not contain financial statements or detailed financial data, nor is it a report like an annual or quarterly report. It is a regulatory compliance filing related to securities and stock exchange listing requirements. The document length is 4033 characters, which is relatively short and focused on certification and confirmation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and certifications that do not fit other specific categories.
2022-01-19 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a short compliance notice under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the issuance of duplicate share certificates due to lost original certificates. It does not contain financial data, management discussion, or report content. It is an official regulatory announcement related to share certificates, which fits best under Regulatory Filings (RNS) as it is a compliance disclosure without substantive financial or operational report content.
2022-01-17 English
Acquisition
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the acquisition and sale of shares by an acquirer (M/s Growel Remedies Limited) in Medicamen Biotech Limited, including shareholding percentages before and after the transaction, mode of acquisition, and dates. This type of document is a notification of a change in significant share ownership levels, which fits the definition of a Major Shareholding Notification (MRQ). The document is not a full financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2022-01-03 English
Trading Plan under PIT
Major Shareholding Notification Classification · 95% confidence The document is an intimation filed by Medicamen Biotech Limited to stock exchanges (BSE and NSE) regarding a disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015. It specifically mentions Regulation 7(2)(b) and Regulation 6(2), and includes Form-C which details the sale of equity shares by a promoter entity (Growel Remedies Limited). The content is a regulatory disclosure about insider trading compliance and shareholding changes by promoters, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive disclosure information. The document fits the category of Major Shareholding Notification (MRQ) because it reports a change in significant share ownership levels by a promoter group as required by SEBI regulations.
2022-01-03 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter from Medicamen Biotech Limited addressed to BSE Limited, dated 31.12.2021. It informs about the closure of the trading window for insiders from January 1, 2022, until two days after the declaration of financial results for the quarter ending December 31, 2021. It mentions the upcoming board meeting date for declaring financial results will be intimated later. The document is a regulatory announcement related to insider trading compliance and trading window closure, not a financial report or earnings release itself. It does not contain financial data or results but is an announcement related to regulatory compliance and trading restrictions. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (1603 characters), and it is not a report publication announcement or certification but a regulatory notice.
2021-12-31 English
Acquisition
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the acquisition and sale of shares by an acquirer (M/s Growel Remedies Limited) in Medicamen Biotech Limited, including shareholding percentages before and after the transaction, mode of acquisition, and dates. This matches the definition of a Major Shareholding Notification, which involves notification of changes in significant share ownership levels crossing thresholds. The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about shareholding changes.
2021-12-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.